NRSN NeuroSense Therapeutics Ltd.
$0.35▲ +4.58%
Healthcare
Other
After hours
$0.34▼ -2.10%
Sep 11, 7:49 PM ET
Volume 218.1K
Avg Volume (10D) 714.1K
Key Metrics & Fundamentals
Market Cap
$658,604
P/E Ratio
–
Div Yield
–%
52W Range
0.25 - 1.33
% vs 50 MA
-33.74%
% vs 200 MA
-55.04%
RSI-14
38.2
MACD Histogram
+0.0000
Beta (1Y vs SPY)
1.12
Gross Rev
$0
Gross Profit
$0
EBITDA
-$1.77M
COGS
–
Operating Exp
$1.77M
Operating Income
-$1.77M
EBIT
-$1.77M
Pretax Income
-$1.80M
Net Income
-$1.80M
Price & Volume History
Loading chart…
Recent News
NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference
PR Newswire · Sep 10, 2026 1:00 PM
NeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS
PR Newswire · Aug 31, 2026 12:45 PM
NeuroSense Issues CEO Letter to Shareholders
PR Newswire · Aug 13, 2026 1:30 PM
NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada
PR Newswire · Aug 6, 2026 3:29 PM
NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS
PR Newswire · Jul 22, 2026 12:30 PM
NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"
PR Newswire · Jul 6, 2026 12:45 PM
NeuroSense Says Phase 2b Trial of PrimeC in Amyotrophic Lateral Sclerosis Meets Primary Endpoint
MT Newswires · Jun 29, 2026 2:00 PM
NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS
PR Newswire · Jun 29, 2026 1:30 PM
NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease
PR Newswire · Jun 25, 2026 1:20 PM
EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots
PR Newswire · Jun 22, 2026 1:00 PM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See NRSN's money flow as a full page
Social Sentiment
Avg +0.62 · 4 posts
DDTradeNewsMy pick for 2025
r/wallstreetbets · Dec 21, 2024
The post presents a strong case for NRSN, highlighting key data, CEO action, and potential partnerships.
very_positive
+0.80
DDDiscussionMy Unconventional Bet on NeuroTech: Could It Be the Next Big Thing?
r/wallstreetbets · Aug 13, 2024
The post discusses NRSN within the context of emerging neurotech companies, indicating some level of interest.
positive
+0.30
NewsDiscussionNRSN finished phase 2 for ALS disease ($673M market) with great results (link in body), an oppty?
r/options · Jul 10, 2024
Significant positive news regarding a potential cure for ALS drives strong bullish sentiment.
positive
+0.80
NewsDiscussionTradeNRSN finished phase 2 for ALS disease ($673M market) with great results (news link in the body), went down yesterday, thinking can be an opportunity to buy.
r/investing · Jul 10, 2024
The post highlights positive results and a potential buying opportunity, indicating bullish sentiment.
positive
+0.60
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.